一分钟看懂
这是一项关于原发性高草酸尿症1型的II 期研究，登记的药物或干预包括YOLT-203；Placebo，当前状态为招募中。登记地点显示中国Birmingham、Aurora、St Louis、Philadelphia有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
YOLT-203；Placebo · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of Alabama at Birmingham (UAB Hospital) · Birmingham
- Childrens Hospital of Colorado · Aurora
- Washington University/Barnes Jewish Hospital · St Louis
- University of Pennsylvania Health System (UPHS) - Penn Medicine · Philadelphia
公开的入选条件
- * You are 6 years old or older.
- * You have been diagnosed with PH1 (primary hyperoxaluria type 1) through genetic testing.
- * Urine tests show that your oxalate levels are not within certain limits (based on at least two 24-hour urine collections).
- * If you take vitamin B6, your dose has been stable for at least 3 months, and you are willing to keep it the same during the study.
- * You (and/or your parent or legal guardian, if you are under 18) understand the study and agree to follow all study requirements, including signing a consent form.
- Exclusion Criteria
- * You have signs that oxalate has affected parts of your body outside the kidneys.
- * Your liver blood tests are not within certain limits.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07587021；登记信息更新于 2026-09-08。